# Daniel Bradbury

> Daniel Bradbury is a seed investor at Equillium backing Biotechnology. See 2 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: Angel Investor
- Fund: Equillium
- Location: San Diego, United States
- Total investments: 2
- Last investment: Oct 2021
- Lead investor: 50%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/bradburydaniel

Daniel Bradbury is a seed investor at Equillium in San Diego focused on Biotechnology and Health Care. Daniel M. Bradbury is Director at Liquid Grids.

## Contacts

5 contacts available for Daniel Bradbury: work email, personal email, work phone, personal phone and socials. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-email/daniel-m-bradbury?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 2 | 100% |
| Health Care | 1 | 50% |
| Life Science | 1 | 50% |
| Neuroscience | 1 | 50% |
| Therapeutics | 1 | 50% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 1 | 50% |
| Series A | 1 | 50% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Amplo Biotechnology | Diseases of the neuromuscular junction have profound health effects including paralysis, breathing and swallowing difficulties. Amplo Biotechnology plans to develop multiple, potentially curative, Adeno-Associated Viral (AAV) therapies for the neuromuscular junction with an initial focus on congenital myasthenic syndromes. Amplo’s lead program,AAV-Dok7, was developed by Professor Yuji Yamanashi's group of the Institute of Medical Science at the University of Tokyo, and is applicable to multiple rare, severe diseases. | $2.2M | Seed | Oct 01, 2021 |  |
| Alume Biosciences | Alume is a biotechnology company, developing nerve-targeted pharmaceutical agents for surgical and therapeutic use. The company's first product, ALM-488, is a fluorescently labeled peptide-dye conjugate that makes human nerves "glow," helping surgeons reduce injury to critical nerves during surgery. During surgery, inadvertentinjury to nerves leads to loss of function, including paralysis, numbness, and decreased quality of life. Alume intends to develop agents including ALM-488 to be used as an adjunct during surgery to help surgeons see nerves better compared to current visualization with white light alone. Alume's technology has the potential to improve the accuracy of nerve identification, decrease operative time, and lead to better outcomes for patients. | $5.5M | Series A | May 01, 2020 |  |

2 of 2 investments shown.

## Co-investors
- [Casdin Capital](https://shizune.co/investors/profile/casdin-capital) — VC Fund, 1 deal together
- [SeedFolio](https://shizune.co/investors/profile/seedfolio) — VC Fund, 1 deal together

## About Equillium

VC Fund · La Jolla, United States

Equillium Inc is a biotechnology company that develops products for autoimmune and inflammatory, or immuno-inflammatory disorders with an unmet medical need. Its primary product candidate is EQ001, which is a clinical-stage first-in-class monoclonal antibody that selectively targets the novel immune checkpoint receptor CD6. CD6 plays a central rolein effector T cell activity, which drives a number of immuno-inflammatory diseases such as graft versus host disease, asthma, uveitis, colitis, lupus, and multiple sclerosis.

5 contacts available at Equillium.

| Name | Title | Profile |
| --- | --- | --- |
| Daniel Bradbury | Chairman of the Board and Chief Executive Officer | https://shizune.co/investors/profile/daniel-m-bradbury |
| Bruce D. Steel | Co-founder, Director, and President and Chief Executive Officer | — |
| Charlie McDermott | Chairman & CEO | — |
| Krishna Polu | Chief Medical Officer | — |
| Stephen Connelly | Co-founder & Chief Scientific Officer | — |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## FAQ

### What does Daniel Bradbury invest in?

Daniel Bradbury invests primarily in Biotechnology, Health Care and Life Science startups, most often at Seed and Series A stage. Most of the 2 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Daniel Bradbury?

Public channels for Daniel Bradbury include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### When did Daniel Bradbury last invest?

The most recent investment recorded for Daniel Bradbury closed in Oct 2021. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co